Teplizumab approval for type 1 diabetes in the USA.

Pfiester, Elizabeth; Adler, Amanda; Lepeska, Molly; Levitt, Naomi; Beran, David; Abidha, Carol; Zafra Tanaka, Jessica Hanae; Gale, Edwin Am; de Beaufort, Carine

dc.contributor.author	Beran, David
dc.contributor.author	Abidha, Carol
dc.contributor.author	Adler, Amanda
dc.contributor.author	de Beaufort, Carine
dc.contributor.author	Lepeska, Molly
dc.contributor.author	Levitt, Naomi
dc.contributor.author	Pfiester, Elizabeth
dc.contributor.author	Zafra Tanaka, Jessica Hanae
dc.contributor.author	Gale, Edwin Am
dc.date.accessioned	2023-02-20T13:28:11Z
dc.date.available	2023-02-20T13:28:11Z
dc.date.issued	2023
dc.identifier.uri	https://hdl.handle.net/20.500.12866/13159
dc.description.abstract	The US Food and Drug Administration's (FDA) approval of teplizumab to delay the onset of type 1 diabetes could be seen as symbolic, because it came a century after the first use of insulin. Teplizumab, an anti-CD3 monoclonal antibody, is now approved in the USA for people at high risk of type 1 diabetes. This approval is a highly welcome development for this population and all those involved in the care and wellbeing of people with type 1 diabetes. However, in our opinion, the approval of teplizumab should be interpreted with caution. A global health perspective must consider evidence, cost, patient preferences, and equity...	en_US
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	Lancet. Diabetes and Endocrinology
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	Teplizumab	en_US
dc.subject	type 1 diabetes	en_US
dc.subject	USA	en_US
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	United States
dc.title	Teplizumab approval for type 1 diabetes in the USA.	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1016/S2213-8587(22)00384-9
dc.relation.issn	2213-8595